Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
暂无分享,去创建一个
Franco Locatelli | Paolo Pedrazzoli | Roberta Schiavo | Cesare Perotti | M. Moroni | P. Pedrazzoli | F. Locatelli | S. Basso | P. Comoli | R. Schiavo | S. Siena | R. Maccario | Salvatore Siena | C. Frasson | Rita Maccario | Chiara Frasson | C. Perotti | Mauro Moroni | Patrizia Comoli | Sabrina Basso | Ornella Carminati | Massimo Labirio | Simona Secondino | O. Carminati | S. Secondino | M. Labirio
[1] G. Botti,et al. Treatment of EBV‐Related Post‐Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV‐Specific T Cells , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[2] B. Robinson,et al. Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.
[3] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Adrian P Gee,et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. , 2005, Blood.
[5] L. Cooper,et al. Induction of Therapeutic T-Cell Responses to Subdominant Tumor-associated Viral Oncogene after Immunization with Replication-incompetent Polyepitope Adenovirus Vaccine , 2004, Cancer Research.
[6] R. Kurzrock,et al. Epstein-Barr Virus and Cancer , 2004, Clinical Cancer Research.
[7] A. Rickinson,et al. Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma , 2004, Journal of Virology.
[8] P. Pedrazzoli,et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Davis,et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. , 2003, Blood.
[10] P. Tam,et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. , 2002, Cancer research.
[11] James F. Jones,et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. , 2002, Blood.
[12] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] H. Heslop,et al. Immunotherapy for Post‐Transplant Lymphoproliferative Disease , 2002, British journal of haematology.
[14] Wiley Interscience,et al. Frequency of Epstein‐Barr virus‐specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients , 2002, Journal of Medical Virology.
[15] E. Bloemena,et al. Identification and prevalence of CD8+ T‐cell responses directed against Epstein‐Barr virus‐encoded latent membrane protein 1 and latent membrane protein 2 , 2002, International journal of cancer.
[16] F. Baldanti,et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.
[17] D. Sidransky,et al. Head and neck cancer. , 2001, The New England journal of medicine.
[18] K. Yuen,et al. Adoptive transfer of autologous Epstein‐Barr virus–specific cytotoxic T cells for nasopharyngeal carcinoma , 2001, International journal of cancer.
[19] J. Cohen,et al. Epstein-Barr virus infection. , 2000, The New England journal of medicine.
[20] S. Leung,et al. CTL Control of EBV in Nasopharyngeal Carcinoma (NPC): EBV-Specific CTL Responses in the Blood and Tumors of NPC Patients and the Antigen-Processing Function of the Tumor Cells1 , 2000, The Journal of Immunology.
[21] H. Mellstedt,et al. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance. , 2000, Anticancer research.
[22] I. Flinn,et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.
[23] S. Burrows,et al. Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation , 1999, Immunological reviews.
[24] M. Christian,et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.
[25] S. Burrows,et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. , 1998, Cancer research.
[26] S. Burrows,et al. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. , 1997, International immunology.
[27] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[28] S. Burrows,et al. Epstein‐Barr virus specific T‐cell response in nasopharyngeal carcinoma patients , 1983, International journal of cancer.
[29] K. Shanmugaratnam,et al. Impaired general cell‐mediated immune functions in vivo and in vitro in patients with nasopharyngeal carcinoma , 1976, International journal of cancer.
[30] Pelayo Vilar,et al. Nasopharyngeal Carcinoma , 1966 .
[31] Ch'en Ch'in-Ts'ai,et al. NASOPHARYNGEAL CARCINOMA , 1959 .